skip to Main Content

NAFLD SUMMIT 2018

20-22 September 2018

Geneva, Switzerland

Prof. Elisabetta Bugianesi, Italy

Prof. Elisabetta Bugianesi MD, PhD, is a clinical researcher graduated from the School of Medicine of the University of Bologna, Italy. He became specialist in Internal Medicine and later PhD in Hepatology at the University of Bologna and Modena. Her post-graduate training included a PhD fellowship at the Cleveland Clinic and at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism and started a pioneering research activity on NAFLD under the guidance of Prof AJ McCullough.

She is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15 years’ experience in the field where she has made a particular impact with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease including the first demonstration of HCC as a complication of NASH-related liver disease, the development of non-invasive markers of fibrosis including the NAFLD Fibrosis score, currently recommended by the EASL-EASD-EASO Clinical practice Guidelines on NAFLD (J Hepatology, 2016) and the involvement in several trials for the treatment of NAFLD/NASH. She has been national principal investigator of FP7 funded Fatty Liver: Inhibition of Progression (FLIP) consortium (2010-2013), assembling the largest cohort to date of highly phenotyped, histologically characterized patients with NAFLD for the genetics work-package and she is currently involved in other two major EU funded research consortia: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €34 million, 2017-2022), where she has the role of national lead for Italy. As clinician, she is a practicing Hepatologist based at the GI Division of the University Hospital “Città della Salute e della Scienza of Torino”, Italy, where she is the lead physician for the Hepatology Outpatient Clinic (with about 1500 patients/year) and the Head of the Gastro-hepatology Laboratory. Contributions to Science 182 publications Impact Factor = 1274 H Index (1990-2017) = 49 (Scopus) N. Citations (1990-2017) = 14584 (Scopus) Positions and Honours Present appointment: Associate Professor of Gastroenterology. Dept of Medical Sciences, Division of Gastroenterology, University of Torino, Italy. International fellowships – PhD Fellow c/o Gastroenterology and Hepatology Division della Cleveland Clinic (Prof AJ McCullough) e c/o Laboratorio di Metabolismo/Spettrometria di Massa (Prof SC Kalhan) della Case Western Reserve University (CWRU), Cleveland (OH), USA (1995 – 1998) Editorial Boards: – Associate Editor of Journal of Hepatology – (2014 – current) – Web editor of Journal of Hepatology – (2011-2014) – Member of the Editorial Board of Hepatology – Member of the Editorial Board of Liver International – Member of the Editorial Board of Digestive and Liver Disease Memberships – Ordine dei Medici (Italy). – Associazione Italiana per lo Studio del Fegato (AISF), member of the AISF NAFLD Expert Committee (AISF) – Associazione Italiana Gastroenterologi Ospedalieri (AIGO), Member of the Scientific Commette – European Association for the Study of the Liver (EASL). – American Association for the Study of the Liver (AASLD)

Read more

Prof. Philip N. Newsome, United Kingdom

Prof. Phillip N. Newsome is the Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham. He graduated from the Medical School at the University of Edinburgh in 1995 and moved to Birmingham in 2007.

He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. Professor Newsome has published over 75 research papers in scientific journals as well as many book chapters in the field of Non-Alcoholic Fatty Liver Disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD. He is editor of a recently published textbook on Liver Transplantation, and chaired the national guidelines for liver transplantation in NAFLD. He sits on the NICE Guideline Development Group for NAFLD.

He has a large laboratory group focussing on the role of cell therapy in liver injury. He has received a range of funding including large project/programme grants (EUFP7, MRC and MRC/Wellcome Clinical Training Fellowships). As a Research Area Lead on the NIHR liver BRU (£13M; 2008-2017) he has established two cutting edge clinical trials which he is the Chief Investigator on. One of these, REALISTIC, is the largest clinical trial of haematopoietic stem cell therapy in patients with liver cirrhosis in Europe/US. He co-ordinates the MERLIN (EU FP7) consortium which includes a clinical trial of mesenchymal stromal cells in patients with primary sclerosing cholangitis. He has driven stem cell research at the University of Birmingham resulting in significant strategic investment in manufacturing facilities such as the Advanced Therapies Facility. The success and significance of his work has led to many approaches from industry such that he has an extensive interaction with many bio-tech companies, ranging from provision of consultancy through to joint research projects.

This research portfolio has led to high impact publications throughout including both original articles (PNAS, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet) and review articles (Gastroenterology, Journal of Hepatology).

Read more

Prof. Vlad Ratziu, France

Prof. Vlad Ratziu is Professor of Hepatology at the Université Pierre et Marie Curie and the Hôpital Pitié-Salpêtrière Medical School in Paris, France. After completing his medical training at the Université Paris Descartes, he completed a 2-year postdoctoral fellowship at the Liver Center at the University of California in San Francisco, USA, and went on to earn a doctoral degree from Université Paris Diderot for his work on the pathophysiology of viral and metabolic liver fibrosis.

Prof. Ratziu’s main research interests are in the field of Non-alcoholic Fatty Liver Disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He has participated in phase I, II, and III studies of non-alcoholic steatohepatitis and has published more than 240 papers in top-tier specialty journals.

He coordinated the FLIP (Fatty Liver Inhibition of Progression) consortium, a program funded by the European 7th Framework Programme (FP7) to study the mechanisms of progression of liver disease in NAFLD in the largest European cohort of patients with NAFLD and to identify potential preventive and therapeutic strategies. He is part of the Steering Committee of the Horizon 2020 NASH EPoS and the IMI2 LITMUS Consortia. He is an associate editor for the Journal of Hepatology, Clinical Liver Diseases and Clinics and Research in Hepatology and Gastroenterology and was also as a member of the editorial board of Hepatology. He currently serves as a Member of the International Advisory Board de The Lancet Gastroenterology & Hepatology

He is part of the organizing Committee of the NASH-TAG meetings (NASH – Therapeutic Agents) www.nash-tag.org

Read more